OA10610A - Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists. - Google Patents

Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists. Download PDF

Info

Publication number
OA10610A
OA10610A OA70033A OA70033A OA10610A OA 10610 A OA10610 A OA 10610A OA 70033 A OA70033 A OA 70033A OA 70033 A OA70033 A OA 70033A OA 10610 A OA10610 A OA 10610A
Authority
OA
OAPI
Prior art keywords
dichloro
benzimidazol
cyclopentanediol
hydroxymethyl
compound
Prior art date
Application number
OA70033A
Other languages
English (en)
Inventor
Laramie Mary Gaster
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9426029.6A external-priority patent/GB9426029D0/en
Priority claimed from GBGB9512920.1A external-priority patent/GB9512920D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA10610A publication Critical patent/OA10610A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA70033A 1994-12-22 1997-06-20 Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists. OA10610A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9426029.6A GB9426029D0 (en) 1994-12-22 1994-12-22 Novel compounds
GBGB9512920.1A GB9512920D0 (en) 1995-06-24 1995-06-24 Novel compounds

Publications (1)

Publication Number Publication Date
OA10610A true OA10610A (en) 2002-09-06

Family

ID=26306239

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70033A OA10610A (en) 1994-12-22 1997-06-20 Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists.

Country Status (27)

Country Link
US (1) US5972951A (de)
EP (1) EP0799226B1 (de)
JP (1) JPH10510821A (de)
CN (1) CN1175256A (de)
AP (1) AP757A (de)
AR (1) AR002011A1 (de)
AT (1) ATE199085T1 (de)
AU (1) AU697361B2 (de)
BG (1) BG61977B1 (de)
BR (1) BR9510419A (de)
CA (1) CA2208244A1 (de)
CZ (1) CZ192397A3 (de)
DE (1) DE69520075T2 (de)
DZ (1) DZ1957A1 (de)
ES (1) ES2153907T3 (de)
FI (1) FI972583L (de)
HU (1) HUT77650A (de)
IL (1) IL116486A0 (de)
MA (1) MA23753A1 (de)
MX (1) MX9704777A (de)
NO (1) NO972910L (de)
NZ (1) NZ298036A (de)
OA (1) OA10610A (de)
PL (1) PL321048A1 (de)
SK (1) SK80297A3 (de)
TR (1) TR199501597A2 (de)
WO (1) WO1996019477A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9519033D0 (en) * 1995-09-18 1995-11-15 Smithkline Beecham Plc Treatment
GB9522845D0 (en) * 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
EP0861257A1 (de) * 1995-11-08 1998-09-02 Smithkline Beecham Plc Spiro-piperdin derivate als 5ht-receptor antagonisten
EP0862565A1 (de) * 1995-11-22 1998-09-09 Smithkline Beecham Plc Tricyclische spiroverbindungen als 5ht1d-rezeptorantagonisten
GB9605883D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Novel compounds
GB9606396D0 (en) * 1996-03-27 1996-06-05 Smithkline Beecham Plc Novel compounds
US6156783A (en) * 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
FR2761069A1 (fr) * 1997-03-20 1998-09-25 Pf Medicament Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments
CA2347095A1 (en) * 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogen-containing condensed heterocyclic derivatives, their production and agent
DE10051981A1 (de) 2000-10-20 2002-05-02 Bayer Ag Substituierte Phenyluracile
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
EP1656370B1 (de) * 2003-06-03 2012-08-15 Rib-X Pharmaceuticals, Inc. Heterocyclische biarylverbindungen und verfahren zu deren herstellung und anwendung
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
US7700808B2 (en) 2005-12-26 2010-04-20 Nissan Chemical Industries, Ltd. 1-3-bis(substituted phenyl)-3-hydroxypropan-1-one or 2-propen-1-one compound, and salt thereof
WO2008131276A1 (en) 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
US8952175B2 (en) 2007-06-27 2015-02-10 Nissan Chemical Industries, Ltd. Method for production of 3-hydroxypropan-1-one compound, method for production of 2-propen-1-one compound and method for production of isoxazoline compound
JO3032B1 (ar) 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
EP4013412B1 (de) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib zur behandlung gastrointestinaler stromakarzinome
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4084779B1 (de) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Zusammensetzungen von 1-(4-brom-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorphenyl)-3-phenylharnstoff
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
US12577211B2 (en) 2020-06-29 2026-03-17 Bacainn Biotherapeutics, Ltd. Probenecid compounds for the treatment of inflammasome-mediated lung disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT533268E (pt) 1991-09-18 2002-02-28 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DE69520075T2 (de) 2001-08-02
AU4343396A (en) 1996-07-10
HUT77650A (hu) 1998-07-28
EP0799226A1 (de) 1997-10-08
PL321048A1 (en) 1997-11-24
SK80297A3 (en) 1998-12-02
WO1996019477A1 (en) 1996-06-27
AR002011A1 (es) 1998-01-07
AP9701006A0 (en) 1997-07-31
BG61977B1 (bg) 1998-11-30
AU697361B2 (en) 1998-10-01
TR199501597A2 (tr) 1996-07-21
NZ298036A (en) 1998-11-25
MX9704777A (es) 1997-10-31
EP0799226B1 (de) 2001-02-07
IL116486A0 (en) 1997-08-14
DZ1957A1 (fr) 2002-02-17
CN1175256A (zh) 1998-03-04
FI972583A0 (fi) 1997-06-17
JPH10510821A (ja) 1998-10-20
CZ192397A3 (en) 1997-09-17
CA2208244A1 (en) 1996-06-27
AP757A (en) 1999-09-06
NO972910L (no) 1997-08-14
US5972951A (en) 1999-10-26
BR9510419A (pt) 1998-05-19
ES2153907T3 (es) 2001-03-16
FI972583A7 (fi) 1997-08-19
DE69520075D1 (de) 2001-03-15
MA23753A1 (fr) 1996-07-01
ATE199085T1 (de) 2001-02-15
BG101715A (bg) 1998-02-27
FI972583L (fi) 1997-08-19
NO972910D0 (no) 1997-06-20

Similar Documents

Publication Publication Date Title
OA10610A (en) Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists.
EP0630368B1 (de) Antivirale nukleosidanaloge
US5808147A (en) Therapeutic nucleosides
FI117629B (fi) Terapeuttisia yhdisteitä
US5399580A (en) Therapeutic nucleosides-uses
WO2017024310A1 (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
AP741A (en) Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring.
AU1438997A (en) 2-amino-5,6-dichlorobenzimidazole derivatives having antiviral activity
US5912356A (en) Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring
MXPA97001789A (en) Antiviral nucleosid analogues containing a substitute benzymidazole base united to a carbocicl ring
CA2992278C (en) Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
HK1003941B (en) Therapeutic nucleosides